Understand the source comparison
Peptides for Immune System: Clinical Applications Comparison
Thymosin-alpha-1 TLR2 agonist, cytokine upregulation Th1 response, dendritic cell activation Subcutaneous injection 1.6–3.2 mg twice weekly Gold standard for immune modulation research. Strongest clinical trial evidence for viral clearance and T-cell function
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymosin-alpha-1
- TLR2 agonist, cytokine upregulation
- Th1 response, dendritic cell activation
- Subcutaneous injection
- 1.6–3.2 mg twice weekly
- Gold standard for immune modulation research. Strongest clinical trial evidence for viral clearance and T-cell function
- Thymalin
- Thymic epithelial support, T-cell maturation
- Thymopoiesis, naive T-cell production
- Intramuscular injection
- 10–30 mg daily for 5–10 days
- Most effective for age-related thymic involution. Limited Western research but extensive Russian clinical use
- LL-37 (Cathelicidin)
- Membrane disruption, LPS neutralization
- Innate immunity, antimicrobial defense
- Topical or subcutaneous
- 5–20 μg/mL in vitro studies
- Powerful direct antimicrobial activity. Human trials sparse, mostly in vitro and animal models
- Epithalon
- Telomerase activation, pineal support
- Indirect via circadian immune regulation
- 5–10 mg daily for 10–20 days
- Promising longevity research but weak direct immune evidence. Primary effects are neuroendocrine
- MK-677
- GH secretagogue, IGF-1 elevation
- Thymic regeneration, hematopoiesis
- Oral capsule
- 12.5–25 mg daily
- Indirect immune support via growth hormone axis. Best for structural immune organ restoration over months